Product Description
LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis.
Mechanisms of Action: Calcineurin Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lipella Pharmaceuticals, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Lipella presented P2 Lichen Planus, Oral results on 2025-09-18 for LP-10
- Clinical Outcomes Reported - Lipella presented P2 Lichen Planus, Oral results on 2025-05-15 for LP-10
Highest Development Phases
Phase 2: Cystitis|Lichen Planus, Oral
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06233591 |
NCT06233591 | P2 |
Active, not recruiting |
Lichen Planus, Oral |
2025-06-01 |
2% |
2025-05-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03129126 |
Safety and Efficacy of LP-10 | P2 |
Completed |
Cystitis |
2023-08-21 |
12% |
2023-12-12 |
Primary Completion Date|Primary Endpoints |